Minimizing RCA in adenovirus production
Minimizing RCA in adenovirus production This whitepaper describes CAP™ Ad cell, designed to minimize replication competent adenovirus (RCA) during production.
Adenovirus viral vectors are commonly used for gene therapy and vaccines. We offer a wide range of robust, scalable upstream and downstream solutions — plus a cell line engineered to minimize replication competent adenovirus (RCA) — and have the technical know-how and experience to support each process step.
Based on the CAP™ cell line, the CAP Ad cell line offers scalable, high-yield production of adenovirus particles ― while minimizing replication-competent adenovirus (RCA). This producer cell line is well-suited for adenovirus production for gene therapy or vaccine applications.
Use our know-how to simplify and accelerate your development and meet your process milestones.
Simplify and streamline your manufacturing process with integrated solutions, speeding time to market and reducing overall cost of goods. A simplified process, using standard, equipment, qualified single-use system designs and components, lowers the risk for operator error.